Volitionrx Ltd (VNRX)

NYSE
Currency in USD
0.668
-0.012(-1.76%)
Closed·
After Hours
0.673+0.005(+0.749%)
·
VNRX Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
VNRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.6500.675
52 wk Range
0.3950.940
Key Statistics
Edit
Prev. Close
0.68
Open
0.668
Day's Range
0.65-0.675
52 wk Range
0.395-0.94
Volume
73.69K
Average Volume (3m)
256.38K
1-Year Change
3.58%
Book Value / Share
-0.28
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VNRX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
2.940
Upside
+340.12%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Volitionrx Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Volitionrx Ltd Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Volitionrx Ltd Earnings Call Summary for Q1/2025

  • VolitionRx Q1 2025 EPS: -$0.06 (missed -$0.04 forecast); Revenue: $250,000 (below $1.31M expected); Stock up 2.86% premarket despite miss
  • Operating expenses down 35% YoY; Company aims for cash neutrality by 2025; Expects to double Nu.Q Discover revenue
  • Pursuing multiple human licensing agreements; In talks with pharma companies for precision medicine applications
  • Cash and equivalents at $2.6M; Net cash used in operations decreased 48% YoY; Current ratio at 0.52 indicates liquidity concerns
  • CEO highlights progress in commercialization; Company focused on securing licensing deals in human diagnostics space
Last Updated: 16/05/2025, 14:14
Read Full Transcript

Compare VNRX to Peers and Sector

Metrics to compare
VNRX
Peers
Sector
Relationship
P/E Ratio
−2.9x−3.3x−0.5x
PEG Ratio
−0.070.080.00
Price/Book
−2.5x2.1x2.6x
Price / LTM Sales
52.6x3.5x3.1x
Upside (Analyst Target)
304.4%27.3%46.1%
Fair Value Upside
Unlock7.8%6.9%Unlock

Analyst Ratings

5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 2.940
(+340.12% Upside)

Earnings

Latest Release
May 16, 2025
EPS / Forecast
-0.06 / -0.04
Revenue / Forecast
250.00K / 1.31M
EPS Revisions
Last 90 days

VNRX Income Statement

People Also Watch

14.828
QBTS
-7.38%
45.580
ASTS
+3.66%
9.18
PHAT
-5.26%
11.73
SEPN
+0.43%
37.480
SMR
+4.05%

FAQ

What Stock Exchange Does Volitionrx Ltd Trade On?

Volitionrx Ltd is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Volitionrx Ltd?

The stock symbol for Volitionrx Ltd is "VNRX."

What Is the Volitionrx Ltd Market Cap?

As of today, Volitionrx Ltd market cap is 68.79M.

What Is Volitionrx Ltd's Earnings Per Share (TTM)?

The Volitionrx Ltd EPS (TTM) is -0.27.

When Is the Next Volitionrx Ltd Earnings Date?

Volitionrx Ltd will release its next earnings report on 12 Aug 2025.

From a Technical Analysis Perspective, Is VNRX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Volitionrx Ltd Stock Split?

Volitionrx Ltd has split 0 times.

How Many Employees Does Volitionrx Ltd Have?

Volitionrx Ltd has 82 employees.

What is the current trading status of Volitionrx Ltd (VNRX)?

As of 12 Jul 2025, Volitionrx Ltd (VNRX) is trading at a price of 0.67, with a previous close of 0.68. The stock has fluctuated within a day range of 0.65 to 0.68, while its 52-week range spans from 0.40 to 0.94.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.